<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Intracranial ependymoma and other ependymal tumors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Intracranial ependymoma and other ependymal tumors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Intracranial ependymoma and other ependymal tumors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Santhosh A Upadhyaya, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher Tinkle, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amar Gajjar, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen A Shih, MD, MS, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ependymomas are a group of glial tumors that typically arise within or adjacent to the ependymal lining of the ventricular system and are thought to be derived from the radial glial cells in the subventricular zone [
         <a href="#rid1">
          1,2
         </a>
         ]. Ependymomas most commonly occur in the posterior fossa, in contact with the fourth ventricle, or in the intramedullary spinal cord; they occasionally occur in the brain parenchyma outside the posterior fossa, and very rarely outside the central nervous system (CNS).
        </p>
        <p>
         Ependymomas account for less than 10 percent of tumors arising in the CNS and 25 percent of primary tumors originating in the spinal cord.
        </p>
        <p>
         The clinical presentation and management of intracranial ependymomas will be reviewed here. Ependymomas arising in the spinal cord are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intracranial ependymomas have a peak incidence in early childhood but can occur at any age [
         <a href="#rid3">
          3
         </a>
         ]. There is a slight male predominance. The median age at diagnosis is five years, and 25 to 40 percent of patients are less than two years old [
         <a href="#rid4">
          4-6
         </a>
         ]. Intracranial ependymomas are uncommon in adults and mostly occur before the age of 40 years. Risk factors for intracranial ependymoma are not well defined.
        </p>
        <p>
         Spinal ependymomas are rare in children and more common in adults, with a median age at diagnosis of 30 to 40 years. There is an increased incidence of intramedullary spinal cord ependymoma in patients with
         <em>
          NF2
         </em>
         -related schwannomatosis (NF2). (See
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors", section on 'Ependymomas'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">
          "
          <i>
           NF2
          </i>
          -related schwannomatosis (formerly neurofibromatosis type 2)", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         The incidence of subependymoma is not well characterized, and many are encountered incidentally or at the time of autopsy. They mainly occur in middle-aged and older adults and are more common in males [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1474096603">
         <span class="h2">
          Histology and classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the World Health Organization (WHO) classification of central nervous system (CNS) tumors, ependymal tumors are classified based on anatomic location, histology, and molecular features. The 2021 revision of the WHO classification (5
         <sup>
          th
         </sup>
         edition, CNS5) recognizes several new entities and subgroups based on molecular genetic features  (
         <a class="graphic graphic_table graphicRef109513" href="/z/d/graphic/109513.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid7">
          7,8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Ependymal tumors'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ependymoma
         </strong>
         – Ependymomas are classified by anatomic site (supratentorial, posterior fossa, and spinal) as well as histology ("classic ependymoma," or WHO grade 2, and "anaplastic ependymoma," or WHO grade 3) and molecular features (see
         <a class="local">
          'Molecular subgroups'
         </a>
         below). These tumors can occur anywhere in the ventricular system or spinal canal; they are most common in the fourth ventricle and spinal cord.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ependymomas are usually well demarcated with frequent areas of calcification, hemorrhage, and cysts. The tumor cells often form ependymal rosettes, which are diagnostic but not always present. Papillary, clear cell, and tanycytic histologic phenotypes are observed but do not have particular clinical significance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is uncertainty regarding the prognostic significance of ependymoma grade, particularly grade 2 versus grade 3 tumors. While some reports have indicated a poorer prognosis for anaplastic ependymoma (grade 3), most notably the Children's Oncology Group (COG) ACNS0121 phase II trial [
         <a href="#rid9">
          9
         </a>
         ], this has not been confirmed in other studies [
         <a href="#rid10">
          10
         </a>
         ], the majority of which were performed retrospectively. Tumor heterogeneity and interobserver variability in grading among neuropathologists may account for the lack of strong correlation with outcomes [
         <a href="#rid11">
          11
         </a>
         ]. Specific genetic alterations and molecular subgroups likely provide better prognostic differentiation and may ultimately replace histologic grading in ependymoma [
         <a href="#rid12">
          12-16
         </a>
         ]. (See
         <a class="local">
          'Molecular subgroups'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subependymoma
         </strong>
         – Subependymomas are rare tumors found in the fourth or lateral ventricles of adults [
         <a href="#rid3">
          3
         </a>
         ]. They have a benign histologic appearance and are classified as WHO grade 1. They consist of a coarse fibrillar matrix with clusters of uniform nuclei and microcysts. Calcifications and hemorrhage can be seen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myxopapillary ependymoma
         </strong>
         – Myxopapillary ependymomas arise almost exclusively in the conus medullaris and filum terminale of the spinal cord  (
         <a class="graphic graphic_diagnosticimage graphicRef120505" href="/z/d/graphic/120505.html" rel="external">
          image 1
         </a>
         ). Molecular analysis suggests that adult and pediatric tumors differ [
         <a href="#rid17">
          17
         </a>
         ]. As of WHO CNS5, myxopapillary ependymomas are designated WHO grade 2, recognizing that the risk of recurrence is similar to that of conventional spinal ependymomas [
         <a href="#rid7">
          7,8,18-21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors", section on 'Myxopapillary ependymoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Molecular subgroups
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genomic alterations are common in ependymomas and may vary based on anatomic location [
         <a href="#rid14">
          14,16,22-34
         </a>
         ]. A number of molecular subgroups are recognized based on comprehensive tumor genetic sequencing and epigenetic profiling [
         <a href="#rid35">
          35-37
         </a>
         ]. Based on these and other data, the following subgroups have emerged but require prospective evaluation to better understand prognostic and therapeutic implications [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Posterior fossa ependymoma group A (PF-EPN-A)
         </strong>
         – PF-EPN-A is a poor prognostic subgroup, found predominantly in infants and young children [
         <a href="#rid39">
          39,40
         </a>
         ]. Tumors exhibit a CpG island methylator phenotype and transcriptional silencing of the polycomb repressive complex 2 (PRC2), leading to repressed expression of differentiation genes [
         <a href="#rid41">
          41
         </a>
         ]. Chromosome 1q gain and possibly 6q loss in PF-EPN-A tumors are prognostic of poor outcomes [
         <a href="#rid9">
          9,10,13,14,16,22,26,42
         </a>
         ]. Such changes are present in approximately 15 to 20 percent of newly diagnosed tumors and up to 60 percent of recurrent tumors [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Loss of nuclear expression of trimethylation of the lysine residue at position 27 on the histone protein (H3K27me3) occurs in PF-EPN-A tumor cells [
         <a href="#rid30">
          30
         </a>
         ], a phenotype initially described in H3 K27-altered diffuse midline gliomas [
         <a href="#rid44">
          44
         </a>
         ]. Mechanistic studies have suggested a shared oncogenic program between PF-EPN-A ependymomas and H3 K27-altered midline gliomas to inhibit the PRC2 complex through the action of peptidyl PRC2 inhibitors [
         <a href="#rid45">
          45,46
         </a>
         ]. The absence of nuclear H3K27me3 immunohistochemical (IHC) staining in the tumor cells on histopathology has clinical relevance as an accurate and reliable way to identify PF-EPN-A subgroup tumors by IHC  (
         <a class="graphic graphic_picture graphicRef120506" href="/z/d/graphic/120506.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid29">
          29,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Posterior fossa ependymoma group B (PF-EPN-B)
         </strong>
         – PF-EPN-B tumors occur in older children and adults and are associated with a better prognosis [
         <a href="#rid36">
          36,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supratentorial ependymoma with
         </strong>
         <strong>
          <em>
           ZFTA
          </em>
         </strong>
         <strong>
          fusion (ST-EPN-ZFTA)
         </strong>
         – A majority (70 to 80 percent) of supratentorial ependymomas harbor an oncogenic fusion between
         <em>
          ZFTA
         </em>
         (previously known as
         <em>
          C11orf95
         </em>
         ) on chromosome 11 and another gene, most commonly
         <em>
          RELA
         </em>
         , the principal effector of NF-κB signaling [
         <a href="#rid48">
          48,49
         </a>
         ]. The
         <em>
          ZFTA
         </em>
         gene fusion is most commonly detected using fluorescence in situ hybridization (FISH) [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'ZFTA fusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In retrospective studies,
         <em>
          ZFTA
         </em>
         fusion has been reported to confer a poor prognosis [
         <a href="#rid48">
          48
         </a>
         ]. This finding has been challenged in prospective studies, however [
         <a href="#rid9">
          9,10,50
         </a>
         ]. Hence, we exercise caution when interpreting and discussing this finding with affected patients and caregivers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other prognostic markers in this subgroup are being investigated. In one retrospective study, the presence of
         <em>
         </em>
         a cyclin-dependent kinase inhibitor 2A (
         <em>
          CDKN2A
         </em>
         ) biallelic deletion conferred a very poor prognosis, but this finding needs to be confirmed in larger prospective studies [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supratentorial ependymoma with
         </strong>
         <strong>
          <em>
           YAP1
          </em>
         </strong>
         <strong>
          fusion (ST-EPN-YAP)
         </strong>
         –
         <em>
          YAP1
         </em>
         fusion tumors constitute a small percentage of supratentorial ependymomas and are enriched in infants. This subgroup may have a better prognosis compared with other subgroups of ependymoma [
         <a href="#rid10">
          10
         </a>
         ], although this will need prospective validation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supratentorial ependymoma without
         </strong>
         <strong>
          <em>
           ZFTA
          </em>
         </strong>
         <strong>
          or
         </strong>
         <strong>
          <em>
           YAP1
          </em>
         </strong>
         <strong>
          fusion
         </strong>
         – A small number of supratentorial ependymomas lack either the
         <em>
          ZFTA
         </em>
         or
         <em>
          YAP
         </em>
         fusion [
         <a href="#rid52">
          52,53
         </a>
         ].
         <em>
         </em>
         These tumors appear to be clinically and molecularly heterogenous, and larger studies are needed to understand the pathogenesis and natural history.
        </p>
        <p>
        </p>
        <p>
         Epigenomic and transcriptomic data suggest that ependymomas are composed of at least nine molecularly, demographically, and clinically distinct disease entities [
         <a href="#rid31">
          31
         </a>
         ]. Still other "omic-based" studies have suggested further heterogeneity within PF-EPN-A [
         <a href="#rid32">
          32
         </a>
         ] and PF-EPN-B [
         <a href="#rid33">
          33
         </a>
         ], while detailed analysis of gene enhancer landscapes of ependymoma provides a framework for drug discovery across and within these molecular subtypes [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H4043607221">
         <span class="h2">
          Presenting signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of patients with ependymoma depends upon the location of the tumor:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased intracranial pressure
         </strong>
         – Most patients with posterior fossa ependymomas have evidence of increased intracranial pressure due to obstructive hydrocephalus. As a result, headache, nausea and vomiting, ataxia, vertigo, and papilledema are common at presentation. Cranial nerve palsies are also common, especially involving cranial nerves VI to X. Brainstem invasion may occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizures and focal deficits
         </strong>
         – Seizures or focal neurologic deficits (eg, hemiparesis) are common presenting signs of supratentorial tumors, which exert mass effect and may have surrounding edema.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myelopathy and radiculopathy
         </strong>
         – Spinal cord ependymomas present with deficits due to involvement of ascending or descending nerve tracts or the exiting peripheral nerves. Specific abnormalities are related to the anatomic level of the tumor. (See
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Leptomeningeal disease
         </strong>
         – Metastatic dissemination of tumor through the cerebrospinal fluid (CSF) is observed in less than 5 percent of patients at the time of initial diagnosis [
         <a href="#rid10">
          10,50
         </a>
         ]. Dissemination can occur with both infratentorial and supratentorial ependymomas. Patients may be minimally symptomatic or have multifocal signs and symptoms referable to cranial nerves or cauda equina disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although historical data suggested a correlation between high-grade histology (classic grade 2 versus anaplastic grade 3) and spinal seeding, more recent data have not confirmed this relationship, and prognosis may depend more on molecular subgroup. (See
         <a class="local">
          'Histology and classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2337183650">
         <span class="h2">
          Anatomic location
         </span>
         <span class="headingEndMark">
          —
         </span>
         The fourth ventricle is the most common site of intracranial ependymomas, and extension into the subarachnoid space occurs frequently, sometimes with encasement of the medulla and upper cervical cord. Supratentorial lesions can be either intraventricular, typically in the lateral ventricles  (
         <a class="graphic graphic_diagnosticimage graphicRef120504" href="/z/d/graphic/120504.html" rel="external">
          image 2
         </a>
         ), or parenchymal.
        </p>
        <p>
         The typical locations in which ependymomas arise differ depending upon patient age:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children
         </strong>
         – In children, approximately 90 percent of ependymomas are intracranial, including 75 percent located in the posterior fossa, while the remaining 10 percent arise in the spinal cord [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – By contrast, approximately 65 percent of ependymomas in adults are spinal, 25 percent are infratentorial, and 10 percent are supratentorial [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors", section on 'Ependymomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of ependymoma requires histologic confirmation but may be suspected preoperatively based on a combination of imaging characteristics, tumor location, and age of the patient. Because gross total resection is so important for intracranial ependymoma as well as most other tumors on the differential diagnosis in children, the diagnosis of ependymoma is typically obtained at the time of open surgery and resection. Biopsy is indicated in selected patients when there is diagnostic uncertainty or prohibitive surgical risk.
        </p>
        <p class="headingAnchor" id="H3441778314">
         <span class="h2">
          Neuroimaging appearance
         </span>
         <span class="headingEndMark">
          —
         </span>
         On magnetic resonance imaging (MRI), ependymomas have a hypointense appearance on T1 and are hyperintense on T2 or proton density images; gadolinium enhancement is usually prominent  (
         <a class="graphic graphic_diagnosticimage graphicRef120503" href="/z/d/graphic/120503.html" rel="external">
          image 3
         </a>
         ). Extension into the foramen of Luschka is commonly observed. Ependymomas often result in hydrocephalus due to obstruction of the fourth ventricle or supratentorial ventricular system by the growing mass, but peritumoral edema is rare. On diffusion-weighted imaging sequences, ependymomas may demonstrate restricted diffusion.
        </p>
        <p>
         The computed tomography (CT) appearance of ependymoma is often hyperdense with homogeneous enhancement; cysts and calcifications are common. The presence of calcifications within a tumor located in the fourth ventricle is highly suggestive but not diagnostic of ependymoma.
        </p>
        <p>
         Subependymomas are nonenhancing, well-demarcated, nodular intraventricular tumors that are isodense on CT. On MRI, they typically appear isointense on T1-weighted images and hyperintense in T2-weighted images [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H876204518">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The radiologic differential diagnosis for posterior fossa tumors in children includes medulloblastoma, pilocytic astrocytoma, embryonal tumors, and choroid plexus tumors. Although histopathology is ultimately required to distinguish among these tumors, certain radiographic features can help inform preoperative suspicion for one over another.
        </p>
        <p>
         For example, ependymomas most often arise from the fourth ventricle and may be accompanied by restricted diffusion on diffusion-weighted images. This feature sometimes differentiates an ependymoma from a pilocytic astrocytoma in the posterior fossa, although it is not sufficiently reliable to guide clinical decisions. In addition, in some patients, ependymoma extends down from the posterior fossa to the cranio-cervical junction, a finding that is rare in other posterior fossa tumors. Posterior fossa ependymomas also often have pronounced extension through the foramina of Luschka, which is less commonly observed in medulloblastoma.
        </p>
        <p>
         In the supratentorial location, glial tumors, embryonal tumors, and choroid plexus carcinoma or papilloma should be considered.
        </p>
        <p class="headingAnchor" id="H317158650">
         <span class="h2">
          Extent of disease evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with suspected or confirmed ependymoma should have an MRI of the brain and entire spine with contrast and a lumbar puncture. Up to 10 percent of patients in some studies show evidence of spinal or leptomeningeal seeding, while other studies report a lower incidence of dissemination at diagnosis [
         <a href="#rid10">
          10,50,56
         </a>
         ].
        </p>
        <p>
         Cerebrospinal fluid (CSF) cytology is important for staging for patients with classic or anaplastic ependymomas. CSF is also important in the staging evaluation of patients with myxopapillary ependymoma if there is concern for disseminated disease on imaging.
        </p>
        <p>
         Ideally, CSF should be obtained preoperatively from the lumbar site, as CSF obtained postoperatively can be more difficult to interpret due to cellular debris from surgery. However, lumbar puncture is often contraindicated at the time of presentation due to obstructive hydrocephalus. CSF sampling postoperatively should be delayed for 10 to 14 days after surgery to allow for surgical debris to clear [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         Although uncommon, the presence of disseminated disease significantly affects both treatment and prognosis. One-third of patients with disseminated disease may be identified only on the basis of positive CSF cytology [
         <a href="#rid50">
          50,58
         </a>
         ]. Due to the rarity of dissemination at diagnosis and because ependymoma cells have a cytologic appearance that overlaps with nonneoplastic or reactive cells, we typically suggest a second CSF sample for confirmation in patients with a single positive cytology.
        </p>
        <p class="headingAnchor" id="H1172916547">
         <span class="h1">
          SURGICAL RESECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial treatment for patients with a suspected ependymoma consists of maximal safe resection.
        </p>
        <p class="headingAnchor" id="H2167895463">
         <span class="h2">
          Extent of resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ependymomas are often located in the posterior fossa, in close proximity to cranial nerves and the brainstem, and surgery carries significant risk. Extent of resection is strongly correlated with oncologic outcomes and survival, however, and patients stand to gain significant benefit from an optimal initial resection. Patients should therefore be referred to a specialized center with pediatric oncologic neurosurgical expertise whenever possible.
        </p>
        <p>
         Although terminology varies, the degree of resection is generally defined as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gross total resection
         </strong>
         – Patients are considered to have a gross total (complete) resection if postoperative MRI shows no residual enhancing or nonenhancing tumor and the surgeon feels that a complete resection was achieved at the time of the operation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Near total resection
         </strong>
         – Near total resection is often used to describe patients who either have a small amount of residual tumor on postoperative MRI (eg, &lt;5 mm) or have no macroscopic tumor visible on postoperative MRI but were noted under the operating microscope to have tumor adherent to a critical structure, such as the brainstem or a cranial nerve, that could not be fully removed safely. For the purposes of treatment and prognosis, these patients are usually considered similarly to those with gross total resection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subtotal resection
         </strong>
         – Subtotal resection includes the remaining patients with residual tumor on postoperative MRI. Other terms that may be used interchangeably include partial resection and incomplete resection.
        </p>
        <p>
        </p>
        <p>
         There are no randomized trials evaluating the extent of surgery. Observational data have consistently indicated that patients undergoing gross total resection have lower rates of local recurrence and better prognosis for long-term survival than those in whom only a partial resection is possible [
         <a href="#rid59">
          59-62
         </a>
         ]. Local recurrences are often more difficult to treat, and the majority of deaths in prospective studies of intracranial ependymoma are due to recurrent ependymoma. (See
         <a class="local">
          'Recurrent disease'
         </a>
         below and
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
         Lesions invading the brainstem can be particularly challenging. Patients with incomplete resections do less well than those with gross total resection. As a result, many centers consider preradiation chemotherapy and a second-look operation if there is residual macroscopic disease that is felt to be safely resectable. (See
         <a class="local">
          'Subtotal resection, age 1 to 21 years'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3764622413">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common potential complications of posterior fossa ependymoma resections are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebellar ataxia
         </strong>
         – Patients may have new or increased ataxia after resection of tumors from the posterior fossa. Lateral hemisphere cerebellar injury can manifest with limb dysmetria, and midline cerebellar injury is more likely to cause gait ataxia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lower cranial nerve damage
         </strong>
         – Cerebellopontine angle lesions can often result in significant lower cranial nerve damage resulting in hemifacial weakness, dysarthria, dysphagia, or hearing loss. At least in infants, recovery of function may follow successful resection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Posterior fossa syndrome
         </strong>
         – Cerebellar mutism, also referred to as posterior fossa syndrome, is a recognized complication of posterior fossa surgery, and emerging data suggest that this is most common when the superior or middle cerebellar peduncles are involved [
         <a href="#rid63">
          63-65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/88801.html" rel="external">
          "Treatment and prognosis of medulloblastoma", section on 'Posterior fossa syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          POSTOPERATIVE THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H895709181">
         <span class="h2">
          Intracranial ependymoma, grade 2 or 3
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ependymomas are invasive primary brain tumors with the potential to disseminate throughout the central nervous system (CNS). Maximal safe resection, adjuvant radiation therapy (RT), and chemotherapy all play a role, depending on the age of the patient, location of the tumor, and extent of resection  (
         <a class="graphic graphic_algorithm graphicRef120568" href="/z/d/graphic/120568.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid37">
          37,66,67
         </a>
         ]. At present, the treatment approach is not based on the molecular subgroup of the tumor.
        </p>
        <p>
         Because of the complexity involved in these cases, patients with ependymomas should be referred to highly specialized centers whenever possible, particularly for infants with subtotal resections and children with positive cerebrospinal fluid (CSF) cytology.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Gross total resection, age 1 to 21 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postoperative management of children &gt;1 year of age who undergo gross or near total resection of an intracranial grade 2 or 3 ependymoma is evolving. RT alone is the standard of care for most such children [
         <a href="#rid66">
          66-69
         </a>
         ]. Although preliminary results from the Children's Oncology Group (COG) ACNS0831 trial suggested a benefit of post-RT maintenance chemotherapy in some patients [
         <a href="#rid70">
          70
         </a>
         ], the data are not yet mature, and final results from the trial are awaited. (See
         <a class="local">
          'Post-RT chemotherapy'
         </a>
         below.)
        </p>
        <p>
         The main exception to postoperative RT in this age group is in patients with supratentorial grade 2 ependymoma who undergo gross total resection. These patients appear to represent a favorable group prognostically and may be considered for observation rather than immediate postoperative RT and chemotherapy. This approach was evaluated in one arm of the completed ACNS0831 cooperative group trial, and the final results are awaited. (See
         <a class="local">
          'Areas of uncertainty and ongoing trials'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3723234178">
         <span class="h4">
          Adjuvant focal RT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following surgery, most children &gt;1 year of age with ependymoma grade 2 or 3 who undergo gross total or near total resection should proceed directly to conformal focal RT.
        </p>
        <p>
         The amount of normal tissue to be included in the RT treatment volume of posterior fossa ependymoma and supratentorial ependymoma has been a source of controversy in the past. While prophylactic cranial irradiation (PCI) was once used in all patients with ependymoma, data from observational series have now defined
         <strong>
          focal
         </strong>
         RT, using contemporary techniques, as the standard of care. Local recurrence is the predominant site of failure, and PCI does not improve survival [
         <a href="#rid4">
          4,5,71,72
         </a>
         ]. More extensive radiation fields are only indicated if there is evidence of tumor dissemination based upon neuroimaging and/or CSF cytology. The reduction in irradiated brain volume is significant in preserving patient quality of life during treatment and long-term, with expected marked decrease in risk of neurocognitive deficits, stroke, and second tumor formation. (See
         <a class="local">
          'Patients with disseminated disease'
         </a>
         below.)
        </p>
        <p>
         Conformal techniques allow irradiation of the tumor bed and an adequate margin of adjacent normal tissue while sparing much of the brain. The current standard dose range to the target for intracranial ependymoma is 54 to 59.4 Gy, and higher doses may be recommended for areas with residual macroscopic disease. The extent of the target volume for focal RT continues to be studied, with shrinking clinical target margins used in the completed ACNS0121 (1 cm) and ACNS0831 (0.5 cm) trials.
        </p>
        <p>
         The outcomes of adjuvant RT in patients with gross or near total resection are illustrated by the COG ACNS0121 phase II trial, which included 118 patients with near total or macroscopic gross total resection of a grade 2 or 3 ependymoma (stratum 3) and 163 patients with microscopic gross total resection of a grade 2 or 3 ependymoma (stratum 4), excluding supratentorial grade 2 tumors, all of whom received postoperative focal RT [
         <a href="#rid9">
          9
         </a>
         ]. With a median follow-up of 7.9 years, 5-year event-free survival (EFS) and overall survival (OS) for stratum 3 were 67 and 83 percent, respectively. Similar EFS and OS results were observed for stratum 4 (70 and 88 percent, respectively). For the combined cohort of 281 children with gross or near total resection of a grade 2 or 3 ependymoma (excluding completely resected grade 2 supratentorial tumors), five-year EFS and OS were 69 and 86 percent, respectively, after focal radiation alone.
        </p>
        <p class="headingAnchor" id="H1649945170">
         <span class="h4">
          Post-RT chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Post-RT chemotherapy is under investigation in patients with ependymoma but has not yet been adopted, pending mature results of the completed COG ACNS0831 trial.
        </p>
        <p>
         The phase III COG ACNS0831 trial enrolled children from 1 to 21 years of age with gross total or near total resection of a newly diagnosed grade 2 or 3 ependymoma and randomly assigned them to receive focal RT alone or focal RT plus maintenance chemotherapy (
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ). Preliminary results were presented at the 19
         <sup>
          th
         </sup>
         International Symposium on Pediatric Neuro-Oncology in December 2020 [
         <a href="#rid70">
          70
         </a>
         ]. The intent-to-treat population consisted of 325 eligible randomized patients with a median age of 4.9 years. With a median follow-up of 3.5 years, there was a trend towards improved EFS in patients randomly assigned to RT plus maintenance chemotherapy (78 versus 72 percent; hazard ratio [HR] 0.73, 90% CI 0.51-1.06). In the prespecified stratum of patients with gross or near total initial resection (286 patients), the improvement in EFS was statistically significant (81 versus 71 percent, p = 0.03). OS data have not yet been presented.
        </p>
        <p>
         Of note, adherence to maintenance chemotherapy was lower than expected, with 27 percent of the chemotherapy arm treated with RT alone, mostly due to patient refusal. In an as-treated analysis excluding patients who did not receive any chemotherapy as well as several in the RT arm who did not receive RT, EFS was greater with chemotherapy (80 versus 71 percent; HR 0.58, 95% CI 0.36-0.94). However, this analysis is subject to bias and therefore of uncertain significance.
        </p>
        <p>
         The final results of ACNS0831, which will include outcomes by molecular subgroups of ependymoma, are not yet available. The ongoing phase III study through the International Society of Paediatric Oncology (SIOP; SIOP-EP-II, NCT02265770), which randomizes patients to adjuvant chemotherapy or observation after surgical resection and RT, will provide additional evidence that could further modify the role of adjuvant chemotherapy in children with newly diagnosed ependymoma. Hence, the role of adjuvant chemotherapy following RT remains unclear and is not recommended in this population.
        </p>
        <p class="headingAnchor" id="H2530398">
         <span class="h3">
          Subtotal resection, age 1 to 21 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with incompletely resected ependymomas of either grade (2 or 3) have consistently worse progression-free survival (PFS) and OS compared with patients who undergo gross total resection. In these high-risk patients, a short course of chemotherapy is suggested postoperatively, followed by second-look surgery if eligible, followed by conformal RT [
         <a href="#rid4">
          4,73
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         appear to be the most active agents for ependymoma, and higher response rates have been observed with more intense combination regimens [
         <a href="#rid74">
          74-79
         </a>
         ]. Patients are typically treated with one to four cycles of multidrug chemotherapy after surgery, and MRI is reviewed to determine whether there is residual disease and, if present, whether the residual disease is felt to be safely resectable. Patients with potentially resectable residual disease then undergo a second surgical debulking prior to proceeding with adjuvant focal RT.
        </p>
        <p>
         RT considerations and dosing are similar to those reviewed above, except that higher doses may be recommended for areas with residual macroscopic disease. (See
         <a class="local">
          'Gross total resection, age 1 to 21 years'
         </a>
         above.)
        </p>
        <p>
         Supporting evidence for this approach includes data from both single-center and multicenter series [
         <a href="#rid4">
          4,9,69,73,80
         </a>
         ]. The largest prospective experience is that of stratum 2 of the COG ACNS0121 phase II trial, which included 64 patients with incompletely resected grade 2 or 3 ependymoma treated with chemotherapy, second surgery (if eligible), and focal RT [
         <a href="#rid9">
          9
         </a>
         ]. With a median follow-up of 7.9 years, EFS and OS were 37 and 70 percent, respectively. The rate of second surgery completion was 39 percent. Chemotherapy consisted of two cycles of a combination of
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         over approximately seven weeks.
        </p>
        <p>
         There does not appear to be a benefit of additional post-RT chemotherapy in this group of patients. In patients enrolled in the ACNS0831 trial who had an initial subtotal resection and achieved a complete response with induction chemotherapy or gross total resection with second-look surgery, preliminary results indicate that patients randomly assigned to RT plus maintenance chemotherapy had similar EFS compared with those assigned to RT alone [
         <a href="#rid70">
          70
         </a>
         ]. Patients who failed to achieve a complete response after induction chemotherapy also did not appear to benefit from post-RT chemotherapy.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Children &lt;1 year of age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although adjuvant RT is the standard treatment for most patients with ependymoma and offers the best chance of durable local control, concerns about potential adverse developmental effects limit its use in very young children [
         <a href="#rid40">
          40
         </a>
         ]. For children less than one year of age, we therefore suggest adjuvant chemotherapy as a bridge to delay the use of adjuvant RT.
        </p>
        <p>
         Those with residual tumor after chemotherapy may be considered for second-look surgery, similar to older children who have undergone subtotal resection, and these patients should be managed at a specialized tertiary care center whenever possible.
        </p>
        <p>
         Above the age of one, the potential benefits of focal RT on local control and long-term survival are generally felt to outweigh the risks, and chemotherapy in place of RT for children age one to three should only be in the context of a formal protocol. (See
         <a class="local">
          'Areas of uncertainty and ongoing trials'
         </a>
         below.)
        </p>
        <p>
         There are no randomized trials comparing immediate RT following surgery with a strategy in which surgery is followed by chemotherapy, and RT is deferred. The potential role of this approach in children up to the age of three to five years is illustrated by three cooperative group series:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 41 children younger than three years of age who presented with nondisseminated disease with the exception of one child, adjuvant multiagent chemotherapy was administered following surgical resection and included either
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         alternating with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         for 14 months, or vincristine, etoposide, and cyclophosphamide for six months. Twenty-nine patients progressed locally after a median of nine months, yet of the 13 survivors, 6 never received RT. The five-year PFS, EFS, and OS rates were 27, 26, and 37 percent, respectively. Among survivors with median follow-up of eight years, there were no significant differences in cognitive outcomes for those receiving or not receiving RT [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 73 children under five years of age who presented without disseminated disease, the initial treatment following maximal surgical resection consisted of seven cycles of chemotherapy [
         <a href="#rid75">
          75
         </a>
         ]. At a median follow-up of five years, the four-year OS was 59 percent, and the five-year EFS was 22 percent. Overall, 36 of 73 children (49 percent) required RT for recurrent disease at a median of 15 months after diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study, 89 children aged three years or less were treated with combination chemotherapy after maximal surgical resection [
         <a href="#rid82">
          82
         </a>
         ]. Of the 80 patients without disseminated disease at presentation, 50 eventually relapsed. At a median follow-up of six years, the five-year EFS and OS rates were 42 and 63 percent, respectively, and the five-year incidence of avoiding RT was 42 percent.
        </p>
        <p>
        </p>
        <p>
         High-dose chemotherapy with autologous stem cell transplantation is considered experimental for ependymoma. In a pilot study, five children with anaplastic ependymoma, all under the age of three, were treated with high-dose chemotherapy and stem cell rescue [
         <a href="#rid83">
          83
         </a>
         ]. Four patients had bulk residual and three presented with disseminated disease. All patients made it to age three without RT, and only one progression has been noted at a median follow-up of 45 months.
        </p>
        <p class="headingAnchor" id="H2595345482">
         <span class="h3">
          Patients with disseminated disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with leptomeningeal dissemination and/or spinal deposits of an intracranial ependymoma generally have a poor prognosis, although survival can be prolonged in some patients with
         <em>
          ZFTA
         </em>
         fusion-positive tumors [
         <a href="#rid50">
          50
         </a>
         ]. Treatment should be individualized. Given challenges in the interpretation of CSF cytology in ependymoma, cytology should be repeated 10 to 14 days postoperatively to confirm results (see
         <a class="local">
          'Extent of disease evaluation'
         </a>
         above), and patients should be referred to a tertiary care center whenever possible.
        </p>
        <p>
         Craniospinal irradiation (CSI) is typically indicated after surgery, but concerns about developmental adverse effects are greater for CSI compared with focal radiation. CSI is usually avoided in children younger than three years of age; in these patients, therapy usually consists of chemotherapy with or without focal RT.
        </p>
        <p class="headingAnchor" id="H683860911">
         <span class="h3">
          Areas of uncertainty and ongoing trials
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Observation alone after gross total resection of supratentorial differentiated/grade 2 tumors
         </strong>
         – Retrospective data indicate that patients with completely resected supratentorial grade 2 ependymomas may do well
         <strong>
          without
         </strong>
         adjuvant RT, and the role of adjuvant RT in this setting remains controversial [
         <a href="#rid62">
          62,84-86
         </a>
         ]. Because most recurrences are local, the rationale of delayed RT is that patients may be spared the potential toxicities of RT upfront, and those who recur after surgery alone can be salvaged with further surgery and postoperative RT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the COG ACNS0121 prospective phase II trial, the five-year PFS was 61 percent in 11 pediatric patients with gross totally resected grade 2 supratentorial ependymoma who were observed after surgery, and all patients were alive at five years [
         <a href="#rid9">
          9
         </a>
         ]. Low patient enrollment in this treatment stratum limited the analysis, and a similar approach was evaluated in the completed ACNS0831 trial. Final results of this strata are not yet available, including the outcomes by molecularly subgroups of supratentorial ependymoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy alone in children &gt;1 year of age
         </strong>
         – Additional studies are needed to establish the role of chemotherapy as a component of primary treatment in young children with ependymoma, particularly with the emergence of conformal radiation techniques that have reduced concerns for radiation-associated toxicities. At present, chemotherapy in place of RT for patients older than one year of age is advised to be used within the context of a formal protocol.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3217921147">
         <span class="h3">
          Adults, age &gt;21 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intracranial ependymoma is uncommon in adults, and no randomized trials have been performed. The treatment approach is based on retrospective data in adults and extrapolation from the experience in children. As in children, extent of initial resection is strongly associated with survival, and maximal safe resection is recommended in all patients [
         <a href="#rid86">
          86-89
         </a>
         ]. (See
         <a class="local">
          'Surgical resection'
         </a>
         above.)
        </p>
        <p>
         Postoperatively, focal RT is suggested for patients with localized grade 3 (anaplastic) ependymoma as well as those with residual disease after resection of a grade 2 ependymoma [
         <a href="#rid66">
          66,67,90,91
         </a>
         ]. Craniospinal RT is reserved for those with evidence of disseminated disease by imaging or CSF cytology [
         <a href="#rid90">
          90
         </a>
         ]. Adjuvant chemotherapy is not known to be beneficial in adults with ependymoma.
        </p>
        <p>
         The role of adjuvant focal RT after gross total resection of a grade 2 ependymoma in adults is uncertain. Consensus guidelines from both the National Comprehensive Cancer Network (NCCN) and the European Association for Neuro-Oncology (EANO) suggest observation after gross total resection of a grade 2 tumor in adults [
         <a href="#rid67">
          67,90
         </a>
         ]. This is based on evidence from retrospective studies of adults with grade 2 ependymoma, in which RT has not been associated with improved PFS or OS for patients with completely resected tumors [
         <a href="#rid92">
          92,93
         </a>
         ]. Others, however, prefer to give postoperative focal RT even after complete resection, particularly if there is any concern about microscopic residual disease at the time of surgery, with the rationale that focal RT is well tolerated, salvage strategies are not proven to be beneficial, and recurrences are associated with morbidity, particularly in the posterior fossa.
        </p>
        <p class="headingAnchor" id="H3941623836">
         <span class="h2">
          Other ependymal tumors
         </span>
        </p>
        <p class="headingAnchor" id="H4134107023">
         <span class="h3">
          Subependymoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subependymomas are often discovered incidentally in older adults, and many presumed subependymomas do not require intervention unless they grow over time and cause symptoms.
        </p>
        <p>
         Patients with large, symptomatic subependymomas often do well after complete resection alone, underscoring the different natural history of these lesions compared with other brain ependymomas [
         <a href="#rid94">
          94
         </a>
         ]. RT is typically reserved for symptomatic or enlarging tumors that cannot be resected.
        </p>
        <p class="headingAnchor" id="H1828942760">
         <span class="h3">
          Spinal ependymomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of spinal cord ependymal tumors is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors", section on 'Ependymomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H367649385">
         <span class="h1">
          FOLLOW-UP AND MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the majority of treatment failures in children with ependymoma develop within five years from diagnosis, late failures and recurrence or progression of the disease beyond five years can be seen, warranting prolonged surveillance beyond the traditional five-year period [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2486107551">
         <span class="h2">
          Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the exact frequency and methods of surveillance imaging may vary according to institutional policies, in general, we recommend the following strategy, most of which is consistent with the ongoing Children's Oncology Group (COG) ACNS0831 trial.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MRI of the brain:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Every three to four months for the first three years after completion of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Every six months from three to five years after completion of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In most centers, patients are transitioned to a survivorship clinic beyond five years after completion of therapy. We recommend annual MRI of the brain for another two to five years from then to detect late recurrences in these children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An MRI of the spine should be considered under the following circumstances:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Annually along with an MRI of the brain.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the presence of symptoms suggestive of spinal cord involvement by the tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         At the time of progression of disease noticed on MRI of the brain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1587804499">
         <span class="h2">
          Survivorship
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who are long-term survivors after treatment for central nervous system (CNS) tumors are at risk for a number of problems, including neurocognitive deficits, focal neurologic deficits, sensorineural hearing loss, growth abnormalities, endocrine abnormalities, radiation necrosis, vasculopathy, and second malignancies [
         <a href="#rid40">
          40
         </a>
         ]. These problems can be due to the damage originally done by the tumor or the treatment (surgery, radiation therapy [RT], and/or chemotherapy) [
         <a href="#rid96">
          96-103
         </a>
         ]. The nature and extent of these problems will be influenced by the location of the tumor and the specific treatment given. (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6253.html" rel="external">
          "Overview of the management of central nervous system tumors in children", section on 'Long-term morbidity'
         </a>
         .)
        </p>
        <p>
         Adult patients can experience significant long-term morbidity including fatigue, numbness, pain, and altered sleep [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=5224" target="_blank">
          Survivorship guidelines
         </a>
         with recommendations for long-term follow-up after treatment of childhood cancer are available from COG [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          RECURRENT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The long-term prognosis for patients with recurrent disease is poor, and while patients can be palliated for extended periods of time, most will eventually succumb within years of relapse. First recurrence is local in approximately two-thirds of patients, metastatic (within the central nervous system) in approximately 20 percent, or a combination in the remaining 10 to 15 percent [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
         While multiple treatment options are available, it is important that patients and caregivers understand the poor long-term prognosis of patients with recurrent or progressive ependymoma after surgical resection and radiation therapy (RT). Careful selection of treatment options for these patients can provide excellent palliation and good quality of life; no single option is considered standard or proven effective [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         Outside of a formal clinical trial, each patient should be managed on a case-by-case basis, taking into account their age, location of the original and recurrent disease, presence of metastases, prior treatment, and functional status. In addition to experimental therapy, multiple approaches have been tried in this population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery
         </strong>
         – Aggressive surgical resection may provide effective palliation in some patients. Chemotherapy with or without RT may have a role in reducing residual or recurrent tumor prior to attempted reresection, all aimed at prolonging the time to further disease progression and death [
         <a href="#rid74">
          74,77,109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation
         </strong>
         – Reirradiation of recurrent tumors may be beneficial and has yielded a salvage rate in carefully selected cases [
         <a href="#rid110">
          110-114
         </a>
         ]. Options include stereotactic radiosurgery (SRS), focal fractionated reirradiation, and craniospinal irradiation (CSI), depending upon the location, patient age, and extent of recurrence [
         <a href="#rid110">
          110,115
         </a>
         ]. Patients treated with focal reirradiation remain at risk for the development of disseminated metastases, and recurrence at the primary site eventually occurs in most patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one of the larger retrospective series of patients treated with aggressive repeat surgical resection and reirradiation at a median of 27 months after first RT, the median progression-free survival (PFS) and overall survival (OS) from the first day of the second RT were 27 and 75 months, respectively [
         <a href="#rid114">
          114
         </a>
         ]. Of the 101 patients in this series, 57 patients (56 percent) experienced subsequent tumor progression following either focal RT or craniospinal and boost reirradiation, and local failure was a component of progression in 35 of these patients (61 percent). Outcomes were most favorable in those patients who experienced a distant-only failure after the first RT course without anaplasia at recurrence and who went on to receive CSI and boost re-RT. The completed phase II RERTEP trial explored this treatment option, with results pending (NCT02125786).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy
         </strong>
         –
         <strong>
         </strong>
         Conventional chemotherapy may provide symptom palliation. There is no single preferred drug or regimen for recurrent ependymoma in children [
         <a href="#rid90">
          90
         </a>
         ]. As described above,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         appear to be the most active agents for ependymoma, based on use in the adjuvant or neoadjuvant setting (see
         <a class="local">
          'Subtotal resection, age 1 to 21 years'
         </a>
         above). In a series of 28 adults with recurrent or progressive intracranial ependymoma, six had an objective response to chemotherapy; the response rate was higher with platinum-based regimens [
         <a href="#rid116">
          116
         </a>
         ]. In addition to platinum-based therapy, oral etoposide, nitrosoureas,
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         have some activity as single agents in patients with recurrent disease [
         <a href="#rid90">
          90,117-121
         </a>
         ]. Responses are usually short lived, and tumor progression after chemotherapy alone usually occurs quickly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular targets
         </strong>
         – There is a growing interest in potential molecular targets for ependymoma, including the epidermal growth factor receptor (EGFR) [
         <a href="#rid16">
          16
         </a>
         ] and vascular endothelial growth factor (VEGF), as well as epigenetic and metabolic regulators [
         <a href="#rid122">
          122-126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In adults, the combination of
         <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">
          temozolomide
         </a>
         and
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         , an oral human epidermal growth factor receptor 2 (HER2) and EGFR inhibitor, is an active regimen for recurrent disease. In a phase II study in 50 adults with recurrent intracranial and spinal ependymoma, median PFS and OS were 7.8 months and 2.25 years, respectively [
         <a href="#rid127">
          127
         </a>
         ]. Two complete and six partial responses were seen, and symptoms stabilized or improved in many patients. In a series of eight adults, six had a partial response to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , with a median time to progression of six months [
         <a href="#rid128">
          128
         </a>
         ], although other retrospective series have not demonstrated significant efficacy [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children, prospective trials are in progress, and all approaches are considered investigational. A clinical trial of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         in 13 children with recurrent or progressive ependymoma failed to show significant activity (no objective responses, median time to progression 2.2 months) [
         <a href="#rid130">
          130
         </a>
         ]. A small phase II study of bevacizumab plus
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         also failed to show benefit in 24 children with recurrent or refractory ependymoma [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2700348285">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intracranial ependymomas in children are associated with poor long-term survival, even after complete resection and adjuvant therapy. With long-term follow-up, 10-year overall survival (OS) is approximately 50 to 70 percent [
         <a href="#rid9">
          9,69,95
         </a>
         ].
        </p>
        <p>
         A number of factors affect the likelihood of disease-free survival after treatment in children [
         <a href="#rid132">
          132
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extent of resection
         </strong>
         – Approximately 80 percent of recurrences are local, underscoring the importance of maximal safe resection [
         <a href="#rid59">
          59,91,133-135
         </a>
         ]. Although the reported degree of benefit has varied, all studies have indicated that patients who can be treated with gross total resection have a better prognosis [
         <a href="#rid4">
          4,59,91,133
         </a>
         ]. Even with gross total resection, however, ependymomas can recur and lead to death in approximately 40 percent of children by 10 years after diagnosis [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor location
         </strong>
         – Comparisons of survival based on tumor location have yielded conflicting results. While several studies have suggested that supratentorial tumors have a better survival [
         <a href="#rid4">
          4,136
         </a>
         ], others have found that patients with infratentorial lesions do better [
         <a href="#rid91">
          91
         </a>
         ]. Involvement of the cervical spinal cord has been associated with decreased survival due to failures outside the primary site [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – In children, older age is associated with better prognosis [
         <a href="#rid135">
          135
         </a>
         ]. Compared with older children, infants may do less well, partly because they have a higher incidence of infratentorial tumors, and partly because they tend not to receive timely adjuvant radiotherapy due to concerns of toxic effects on brain development.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histologic grade
         </strong>
         – The prognostic significance of histology grade (2 versus 3) in ependymoma remains controversial. While some studies have found that grade 3 tumors are associated with worse outcome compared with grade 2 tumors [
         <a href="#rid9">
          9,138
         </a>
         ], other studies have been less conclusive given the difficulty in arriving at a definitive diagnosis of the grade of tumor [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="local">
          'Histology and classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular genetic subgroups
         </strong>
         – A number of molecular subgroups have been identified based on comprehensive genomic sequencing of series of ependymoma samples, which ultimately may prove more powerful than histology for prognostic differentiation. (See
         <a class="local">
          'Molecular subgroups'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional molecular alterations
         </strong>
         – Copy number gain of chromosome arm 1q in posterior fossa ependymoma of childhood has been associated with unfavorable outcome in a number of retrospective series [
         <a href="#rid13">
          13,16,22,26,42
         </a>
         ]. Subsequent data from prospective clinical trials have supported the association of 1q gain in posterior fossa ependymoma group A (PF-EPN-A) tumors in children, while the prognostic implication of 1q gain remains to be fully defined in posterior fossa ependymoma group B (PF-EPN-B) tumors [
         <a href="#rid9">
          9,10,22,33
         </a>
         ]. In tumors with
         <em>
          ZFTA
         </em>
         fusion,
         <em>
          CDKN2A
         </em>
         deletion may identify a subset with a particularly poor prognosis, but further studies are needed [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4195931355">
         <span class="h2">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intracranial ependymoma is less common in adults, and outcomes data are more limited. Two large European multi-institution series that included a total of 222 patients and 123 patients from a single United States institution analyzed the outcomes and prognostic factors for adults with intracranial ependymomas [
         <a href="#rid87">
          87,88,139
         </a>
         ]. In these series, the five-year survival rate ranged from 67 to 85 percent, and the 10-year survival varied from 50 to 77 percent. On multivariate analysis, factors associated with a poor prognosis included high histologic grade, incomplete surgical resection [
         <a href="#rid140">
          140
         </a>
         ], location [
         <a href="#rid139">
          139,141
         </a>
         ], and a Karnofsky Performance Status ≤80  (
         <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid88">
          88
         </a>
         ]. The prognostic importance of incomplete resection has also been observed in a population-based study of both adults and children with ependymoma using the Surveillance Epidemiology and End Results (SEER) database [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2779210042">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/130511.html" rel="external">
          "Society guideline links: Primary brain tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Intracranial ependymomas have a peak incidence in early childhood, with a median age at diagnosis of five years. In adults, ependymomas more commonly occur in the spinal cord. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors", section on 'Ependymomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         – The three major types of ependymoma are subependymoma (World Health Organization [WHO] grade 1), myxopapillary ependymoma (WHO grade 2), and ependymoma (WHO grade 2 or 3, may be supratentorial, posterior fossa, or spinal)  (
         <a class="graphic graphic_table graphicRef109513" href="/z/d/graphic/109513.html" rel="external">
          table 1
         </a>
         ). For intracranial ependymomas, the distinction between grade 2 and grade 3 is of uncertain prognostic significance and may be replaced by molecular stratification in the future. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Signs and symptoms depend on tumor location. For posterior fossa tumors, children often present with headache, nausea and vomiting, ataxia, vertigo, and papilledema due to obstructive hydrocephalus and tumor mass effect on the cerebellum. (See
         <a class="local">
          'Presenting signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis and staging
         </strong>
         – The diagnosis of intracranial ependymoma requires histologic confirmation. Ependymoma may be suspected preoperatively based on imaging characteristics, tumor location, and patient age. Staging with complete spine MRI and cerebrospinal fluid (CSF) testing should be performed, as up to 10 percent of patients have disseminated disease at the time of diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical resection
         </strong>
         – The initial treatment for patients with a suspected ependymoma is maximal safe resection. Gross total resection is the goal but is not always feasible due to brainstem involvement or proximity to other critical structures. Patients should be referred to a specialized center with pediatric oncologic neurosurgical expertise whenever possible. (See
         <a class="local">
          'Surgical resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative therapy
         </strong>
         – Intracranial ependymomas have the potential to recur and disseminate throughout the nervous system. Postoperative radiation therapy (RT) and/or chemotherapy is therefore required in most patients, even in the presence of a negative staging evaluation  (
         <a class="graphic graphic_algorithm graphicRef120568" href="/z/d/graphic/120568.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children 1 to 21 years of age with an intracranial ependymoma grade 2 or 3 who undergo gross total or near total resection upon initial surgical resection, we recommend postoperative focal RT (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ) (see
         <a class="local">
          'Gross total resection, age 1 to 21 years'
         </a>
         above). Potential exceptions include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For children between one and three years of age who undergo gross total resection, chemotherapy may be an alternative to immediate RT in an effort to avoid the neurologic complications of RT in young children. However, this is advised in the context of a formal clinical trial. (See
         <a class="local">
          'Children &lt;1 year of age'
         </a>
         above and
         <a class="local">
          'Areas of uncertainty and ongoing trials'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For children with a supratentorial grade 2 ependymoma who undergo gross total resection, observation may be an alternative to adjuvant therapy. (See
         <a class="local">
          'Areas of uncertainty and ongoing trials'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most children 1 to 21 years of age who undergo subtotal resection of an intracranial ependymoma (WHO grade 2 or 3), we suggest postoperative chemotherapy followed by second-look surgery, if eligible, followed by adjuvant focal RT, rather than immediate postoperative RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Subtotal resection, age 1 to 21 years'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children less than one year of age with an intracranial ependymoma, we suggest adjuvant chemotherapy as a bridge to delay the use of adjuvant RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Children &lt;1 year of age'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with leptomeningeal dissemination and/or spinal deposits at the time of diagnosis have a poor prognosis. Treatment typically consists of craniospinal RT or multiagent chemotherapy, depending on the age of the patient. (See
         <a class="local">
          'Patients with disseminated disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For adults with a grade 3 intracranial ependymoma and those with an incompletely resected grade 2 ependymoma, we suggest immediate postoperative focal RT, rather than no RT or RT plus chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Decisions about postoperative RT after gross total resection of a grade 2 ependymoma are individualized. (See
         <a class="local">
          'Adults, age &gt;21 years'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Patients with intracranial ependymoma remain at risk for local and distant recurrence after completion of initial therapy. In children, we conduct regular imaging and clinical surveillance for 7 to 10 years after completion of therapy. (See
         <a class="local">
          'Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Even with maximal therapy, intracranial ependymomas are associated with significant risk of recurrence and decreased long-term survival. With long-term follow-up in children, 10-year overall survival (OS) is approximately 50 to 70 percent. (See
         <a class="local">
          'Prognosis'
         </a>
         above and
         <a class="local">
          'Recurrent disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1916586189">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Mark Kieran, MD, PhD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Shuangshoti S, Rushing EJ, Mena H, et al. Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer 2005; 103:2598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8:323.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), International Agency for Research on Cancer, 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massimino M, Miceli R, Giangaspero F, et al. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro Oncol 2016; 18:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 2009; 10:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain MC. Ependymomas. Curr Neurol Neurosci Rep 2003; 3:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23:1231.
          </a>
         </li>
         <li class="breakAll">
          Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant TE, Bendel AE, Sabin ND, et al. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. J Clin Oncol 2019; 37:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro Oncol 2019; 21:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011; 10:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milde T, Hielscher T, Witt H, et al. Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 2012; 22:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godfraind C, Kaczmarska JM, Kocak M, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol 2012; 124:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002; 86:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002; 161:2133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006; 12:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton VN, Donson AM, Kleinschmidt-DeMasters BK, et al. Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol 2010; 20:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akyurek S, Chang EL, Yu TK, et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center. J Neurooncol 2006; 80:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant TE, Kiehna EN, Thompson SJ, et al. Pediatric low-grade and ependymal spinal cord tumors. Pediatr Neurosurg 2000; 32:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agbahiwe HC, Wharam M, Batra S, et al. Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys 2013; 85:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Halabi H, Montes JL, Atkinson J, et al. Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas. Pediatr Blood Cancer 2010; 55:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015; 27:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousseau A, Idbaih A, Ducray F, et al. Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. J Neurooncol 2010; 97:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 2005; 7:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang B, Starostik P, Schraut H, et al. Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol 2003; 106:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010; 28:3182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wani K, Armstrong TS, Vera-Bolanos E, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 2012; 123:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang I, Nagasawa DT, Kim W, et al. Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas. J Clin Neurosci 2012; 19:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panwalkar P, Clark J, Ramaswamy V, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 2017; 134:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayliss J, Mukherjee P, Lu C, et al. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med 2016; 8:366ra161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mack SC, Taylor MD. Put away your microscopes: the ependymoma molecular era has begun. Curr Opin Oncol 2017; 29:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pajtler KW, Wen J, Sill M, et al. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 2018; 136:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavalli FMG, Hübner JM, Sharma T, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 2018; 136:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mack SC, Pajtler KW, Chavez L, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature 2018; 553:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010; 466:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 2017; 133:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison DW, Aldape KD, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol 2020; 30:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramaswamy V, Hielscher T, Mack SC, et al. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis. J Clin Oncol 2016; 34:2468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zapotocky M, Beera K, Adamski J, et al. Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer 2019; 125:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014; 506:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baroni LV, Sundaresan L, Heled A, et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol 2021; 23:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donson AM, Bertrand KC, Riemondy KA, et al. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study. Neuro Oncol 2023; 25:1854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis PW, Müller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hübner JM, Müller T, Papageorgiou DN, et al. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Neuro Oncol 2019; 21:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain SU, Do TJ, Lund PJ, et al. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat Commun 2019; 10:2146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman RJ, Ghasemi DR, Andreiuolo F, et al. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study. Neuro Oncol 2023; 25:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 2014; 506:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietsch T, Wohlers I, Goschzik T, et al. Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway. Acta Neuropathol 2014; 127:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benesch M, Mynarek M, Witt H, et al. Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist 2019; 24:e921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jünger ST, Andreiuolo F, Mynarek M, et al. CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathol 2020; 140:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zschernack V, Jünger ST, Mynarek M, et al. Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathol 2021; 141:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuoka K, Kanemura Y, Shofuda T, et al. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun 2018; 6:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg 2009; 110:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maiuri F, Gangemi M, Iaconetta G, et al. Symptomatic subependymomas of the lateral ventricles. Report of eight cases. Clin Neurol Neurosurg 1997; 99:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fangusaro J, Van Den Berghe C, Tomita T, et al. Evaluating the incidence and utility of microscopic metastatic dissemination as diagnosed by lumbar cerebro-spinal fluid (CSF) samples in children with newly diagnosed intracranial ependymoma. J Neurooncol 2011; 103:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsay HB, Massimino M, Avula S, et al. Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 2022; 23:e393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno L, Pollack IF, Duffner PK, et al. Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma. J Pediatr Hematol Oncol 2010; 32:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmermann B, Kortmann RD, Kühl J, et al. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 2000; 46:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez D, Cheung MC, Housri N, et al. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res 2009; 156:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amirian ES, Armstrong TS, Aldape KD, et al. Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology 2012; 39:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aizer AA, Ancukiewicz M, Nguyen PL, et al. Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol 2013; 115:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doxey D, Bruce D, Sklar F, et al. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg 1999; 31:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McEvoy SD, Lee A, Poliakov A, et al. Longitudinal cerebellar diffusion tensor imaging changes in posterior fossa syndrome. Neuroimage Clin 2016; 12:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu JF, Dineen RA, Avula S, et al. Development of a pre-operative scoring system for predicting risk of post-operative paediatric cerebellar mutism syndrome. Br J Neurosurg 2018; 32:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reni M. Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. Forum (Genova) 2003; 13:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudà R, Reifenberger G, Frappaz D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol 2018; 20:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant TE. Current Clinical Challenges in Childhood Ependymoma: A Focused Review. J Clin Oncol 2017; 35:2364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritzmann TA, Chapman RJ, Kilday JP, et al. SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study. Neuro Oncol 2022; 24:936.
          </a>
         </li>
         <li class="breakAll">
          Smith A, Onar-Thomas A, Ellison D, et al. Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years. Abstract and presentation. The 19th International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan, December 2020.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 2005; 75:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RE. Review of radiotherapy dose and volume for intracranial ependymoma. Pediatr Blood Cancer 2004; 42:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Poppel M, Klimo P Jr, Dewire M, et al. Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience. J Neurosurg Pediatr 2011; 8:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siffert J, Allen JC. Chemotherapy in recurrent ependymoma. Pediatr Neurosurg 1998; 28:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grill J, Le Deley MC, Gambarelli D, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001; 19:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain MC. Salvage chemotherapy for recurrent spinal cord ependymona. Cancer 2002; 95:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gornet MK, Buckner JC, Marks RS, et al. Chemotherapy for advanced CNS ependymoma. J Neurooncol 1999; 45:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst 1999; 15:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouladi M, Gururangan S, Moghrabi A, et al. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 2009; 115:3243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garvin JH Jr, Selch MT, Holmes E, et al. Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massimino M, Gandola L, Barra S, et al. Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy. Int J Radiat Oncol Biol Phys 2011; 80:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007; 8:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung KW, Lim DH, Lee SH, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age. J Neurooncol 2012; 107:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hukin J, Epstein F, Lefton D, Allen J. Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 1998; 29:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma L, Celli P, Mariottini A, et al. The importance of surgery in supratentorial ependymomas. Long-term survival in a series of 23 cases. Childs Nerv Syst 2000; 16:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg 2005; 102:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reni M, Brandes AA, Vavassori V, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004; 100:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metellus P, Barrie M, Figarella-Branger D, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007; 130:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollon T, Nguyen V, Smith BW, et al. Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. J Neurosurg 2016; 125:410.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005; 61:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metellus P, Guyotat J, Chinot O, et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol 2010; 12:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nuño M, Yu JJ, Varshneya K, et al. Treatment and survival of supratentorial and posterior fossa ependymomas in adults. J Clin Neurosci 2016; 28:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kweh BTS, Rosenfeld JV, Hunn M, Tee JW. Tumor characteristics and surgical outcomes of intracranial subependymomas: a systematic review and meta-analysis. J Neurosurg 2022; 136:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marinoff AE, Ma C, Guo D, et al. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol 2017; 135:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broniscer A, Ke W, Fuller CE, et al. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer 2004; 100:2246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiegler BJ, Bouffet E, Greenberg ML, et al. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 2004; 22:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A Pediatric Oncology Group study. Ann Neurol 1998; 44:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: A population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devarahally SR, Severson RK, Chuba P, et al. Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence. Pediatr Hematol Oncol 2003; 20:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bass JK, Hua CH, Huang J, et al. Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer. J Clin Oncol 2016; 34:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer 2011; 117:5133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zacharoulis S, Ashley S, Moreno L, et al. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst 2010; 26:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desrousseaux J, Claude L, Chaltiel L, et al. Respective Roles of Surgery, Chemotherapy, and Radiation Therapy for Recurrent Pediatric and Adolescent Ependymoma: A National Multicentric Study. Int J Radiat Oncol Biol Phys 2023; 117:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massimino M, Barretta F, Modena P, et al. Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol. Neuro Oncol 2022; 24:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant TE. Current management of childhood ependymoma. Oncology (Williston Park) 2002; 16:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 2008; 71:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stafford SL, Pollock BE, Foote RL, et al. Stereotactic radiosurgery for recurrent ependymoma. Cancer 2000; 88:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu AK, Foreman NK, Gaspar LE, et al. Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children. Pediatr Blood Cancer 2009; 52:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouffet E, Hawkins CE, Ballourah W, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys 2012; 83:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsang DS, Burghen E, Klimo P Jr, et al. Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. Int J Radiat Oncol Biol Phys 2018; 100:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsang DS, Murray L, Ramaswamy V, et al. Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. Neuro Oncol 2019; 21:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandes AA, Cavallo G, Reni M, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer 2005; 104:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudà R, Bosa C, Magistrello M, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol 2016; 18:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komori K, Yanagisawa R, Miyairi Y, et al. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression. Pediatr Blood Cancer 2016; 63:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright KD, Daryani VM, Turner DC, et al. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 2015; 17:1620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain MC. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol 2001; 24:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandri A, Massimino M, Mastrodicasa L, et al. Treatment with oral etoposide for childhood recurrent ependymomas. J Pediatr Hematol Oncol 2005; 27:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michealraj KA, Kumar SA, Kim LJY, et al. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell 2020; 181:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gojo J, Englinger B, Jiang L, et al. Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell 2020; 38:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arabzade A, Zhao Y, Varadharajan S, et al. ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discov 2021; 11:2200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupp R, Ruff L, Terranova S, et al. ZFTA Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors. Cancer Discov 2021; 11:2216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng T, Ghasemi DR, Okonechnikov K, et al. Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. Cancer Discov 2021; 11:2230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert MR, Yuan Y, Wu J, et al. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol 2021; 23:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology 2009; 73:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couec ML, André N, Thebaud E, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer 2012; 59:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gururangan S, Fangusaro J, Young Poussaint T, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012; 14:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeWire M, Fouladi M, Turner DC, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol 2015; 123:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pajtler KW, Pfister SM, Kool M. Molecular dissection of ependymomas. Oncoscience 2015; 2:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Healey EA, Barnes PD, Kupsky WJ, et al. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991; 28:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin MP, Marcus RB Jr, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998; 40:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998; 30:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 1999; 21:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shu HK, Sall WF, Maity A, et al. Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer 2007; 110:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De B, Khakoo Y, Souweidane MM, et al. Patterns of relapse for children with localized intracranial ependymoma. J Neurooncol 2018; 138:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong TS, Vera-Bolanos E, Bekele BN, et al. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol 2010; 12:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitanovics D, Bálint K, Hanzély Z, et al. Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res 2010; 16:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. J Neurooncol 2012; 107:183.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5224 Version 59.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15861411" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16226707" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Radial glia cells are candidate stem cells of ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16226707" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Radial glia cells are candidate stem cells of ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27194148" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19274783" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12691623" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30811284" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30976811" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21627842" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22568867" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Nestin expression identifies ependymoma patients with poor outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22526017" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11953826" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Genetic abnormalities detected in ependymomas by comparative genomic hybridisation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12466129" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16609018" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19793339" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Unique molecular characteristics of pediatric myxopapillary ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16648988" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10765136" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pediatric low-grade and ependymal spinal cord tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22713833" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20806362" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25965575" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19865800" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15701279" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12898154" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Human ependymomas reveal frequent deletions on chromosomes 6 and 9.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20516456" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Molecular staging of intracranial ependymoma in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22322993" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A prognostic gene expression signature in infratentorial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22516549" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28733933" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27881822" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885433" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Put away your microscopes: the ependymoma molecular era has begun.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29909548" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30019219" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Heterogeneity within the PF-EPN-B ependymoma subgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29258295" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20639864" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cross-species genomics matches driver mutations and cell compartments to model ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21840481" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27858204" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32502305" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27269943" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30768777" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24553142" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33580238" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37246777" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23539183" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30923826" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31086175" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36916248" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24553141" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24562983" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30850560" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32514758" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33481105" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Supratentorial ependymoma in childhood: more than just RELA or YAP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30514397" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19061350" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9107462" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Symptomatic subependymomas of the lateral ventricles. Report of eight cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21038109" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Evaluating the incidence and utility of microscopic metastatic dissemination as diagnosed by lumbar cerebro-spinal fluid (CSF) samples in children with newly diagnosed intracranial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35901835" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20463607" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10661334" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19577759" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22846789" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24057324" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10708354" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Posterior fossa syndrome: identifiable risk factors and irreversible complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27689022" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Longitudinal cerebellar diffusion tensor imaging changes in posterior fossa syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29433337" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Development of a pre-operative scoring system for predicting risk of post-operative paediatric cerebellar mutism syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14732890" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29194500" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : EANO guidelines for the diagnosis and treatment of ependymal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28640697" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Current Clinical Challenges in Childhood Ependymoma: A Focused Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35018471" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35018471" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16195801" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ependymoma: new therapeutic approaches including radiation and chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15049020" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Review of radiotherapy dose and volume for intracranial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21882915" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9782208" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Chemotherapy in recurrent ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230470" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12209682" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Salvage chemotherapy for recurrent spinal cord ependymona.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10728911" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Chemotherapy for advanced CNS ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10550587" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Chemotherapy for intracranial ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19484793" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Carboplatin-based primary chemotherapy for infants and young children with CNS tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22949057" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20646868" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17644039" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22081297" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9755311" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Treatment of intracranial ependymoma by surgery alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10804053" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The importance of surgery in supratentorial ependymomas. Long-term survival in a series of 23 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871504" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Is gross-total resection sufficient treatment for posterior fossa ependymomas?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15022290" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A multicenter study of the prognosis and treatment of adult brain ependymal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449478" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26745489" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26745489" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15667957" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Postoperative radiation therapy for grade II and III intracranial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20484442" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26810473" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Treatment and survival of supratentorial and posterior fossa ependymomas in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34416731" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Tumor characteristics and surgical outcomes of intracranial subependymomas: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28733870" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15139071" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14966095" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Change in neurocognitive functioning after treatment with cranial radiation in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9749596" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11058888" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11878577" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Prognostic factors and secondary malignancies in childhood medulloblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11309438" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14578032" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26811531" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21538344" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15576413" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20039045" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37437811" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Respective Roles of Surgery, Chemotherapy, and Radiation Therapy for Recurrent Pediatric and Adolescent Ependymoma: A National Multicentric Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34605902" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12108890" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Current management of childhood ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18406885" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A retrospective study of surgery and reirradiation for recurrent ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10679657" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Stereotactic radiosurgery for recurrent ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19260098" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22245198" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29229328" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30452715" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15912507" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26323606" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26305586" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26541630" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11275460" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16189442" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Treatment with oral etoposide for childhood recurrent ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32445698" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32663469" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33741710" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33741711" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : ZFTA Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33879448" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33085768" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19917990" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Bevacizumab for recurrent ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22287258" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23019233" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25859842" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26682265" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Molecular dissection of ependymomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1876244" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : The prognostic significance of postoperative residual tumor in ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9531369" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Ependymoma: results, prognostic factors and treatment recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9589080" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10363853" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17559078" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Childhood intracranial ependymoma: twenty-year experience from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29511977" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Patterns of relapse for children with localized intracranial ependymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20511182" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19728165" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Ependymoma in adults: surgery, reoperation and radiotherapy for survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21952907" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Predictors of survival among older adults with ependymoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
